<DOC>
	<DOCNO>NCT00096343</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel carboplatin , work different way stop tumor cell divide stop grow die . Giving chemotherapy surgery may shrink tumor remove . Combining paclitaxel carboplatin may kill tumor cell . PURPOSE : This phase II trial study well give paclitaxel together carboplatin work treat woman undergo surgery newly diagnose , locally advanced breast cancer .</brief_summary>
	<brief_title>Paclitaxel Carboplatin Treating Women Who Are Undergoing Surgery Newly Diagnosed , Locally Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine clinical pathological response woman newly diagnose , locally advance operable breast cancer treat neoadjuvant chemotherapy comprise paclitaxel carboplatin . - Evaluate specific biomarkers prognostic value marker response/resistance patient treated regimen . - Determine tolerability toxicity regimen patient . OUTLINE : This open-label study . Patients non-palpable lymph node undergo sentinel lymph node biopsy within 4 week begin neoadjuvant chemotherapy . All patient receive paclitaxel IV 3 hour follow carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients undergo lumpectomy modify radical mastectomy . Patients positive sentinel lymph node biopsy palpable axillary adenopathy undergo axillary lymph node dissection . All patient undergo lumpectomy mastectomy high-risk disease also undergo radiotherapy . Patients refuse lumpectomy mastectomy due persistence disease may undergo core needle biopsy . PROJECTED ACCRUAL : A total 30 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive ductal carcinoma invasive lobular carcinoma breast meeting follow stage criterion : T2 , T3 , T4ac N02 M0 Inflammatory breast cancer ( stage IIIB ) allow Measurable disease mammogram ultrasound Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Not specify Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Hepatic AST ALT ≤ 1.5 time upper limit normal ( ULN ) Renal Creatinine ≤ 1.2 time ULN OR Creatinine clearance ≥ 50 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No comorbid medical condition would preclude study participation No comorbid infection would preclude study participation No clinically significant peripheral neuropathy ( &gt; grade 1 ) No prior significant allergic reaction drug contain Cremophor , teniposide , cyclosporine , vitamin K No dementia alter mental status would prohibit understanding informed consent No primary malignancy except nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent prophylactic growth factor Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery At least 3 week since prior surgery Other No concurrent anticancer drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>invasive ductal breast carcinoma</keyword>
	<keyword>invasive lobular breast carcinoma</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>